Navigation Links
Repligen Licenses Rights to Use of HDAC3 Inhibitors for Memory Disorders
Date:1/20/2011

WALTHAM, Mass., Jan. 20, 2011 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN) announced today that it has entered into an exclusive license agreement with the University of California, Irvine (UCI) for a patent application covering the use of histone deacetylase 3 (HDAC3) inhibitors for the treatment of disorders involving preservation or extinction of memory including Alzheimer's disease, memory impairment and post traumatic stress disorder.  The patent application is based on work conducted at UCI by Dr. Marcelo A. Wood, which demonstrated that one of Repligen's HDAC3 inhibitors improved both the acquisition and persistence of long-term memory in an animal model.  These data were published in the January 12th issue of The Journal of Neuroscience in a manuscript entitled "HDAC3 Is a Critical Negative Regulator of Long-Term Memory Formation" (McQuown, S., et al., J. Neurosci. (2011) 31:764 –774).  Under the terms of the license agreement, UCI will receive an upfront payment, development milestones and royalties upon successful commercialization of an HDAC3 inhibitor for certain memory disorders.  Upon issue, the patent will remain in force until 2031 prior to any regulatory extensions.

"These new data indicate that HDAC3 inhibitors should be further evaluated for use in a variety of disorders in which the acquisition or extinction of a long-term memory is a factor," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "We intend to continue to investigate the potential of our selective HDAC3 inhibitors in a variety of disease models."

The manuscript published in The Journal of Neuroscience examined the role of HDAC3 inhibitors in long-term memory using a combined genetic and pharmacologic approach.  In the study, a genetic approach was used to delete HDAC3 in the hi
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
3. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
4. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
5. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
6. Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A
7. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
8. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
9. Repligen Announces Conference Call of First Quarter Fiscal Year 2011 Results
10. Repligen to Present at the Rodman & Renshaw Annual Global Investment Conference
11. Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014  Nearly 8,000 attendees will converge in ... Retail Business Conference (RBC), taking place July 23-26 at ... event encourages pharmacists to "Lead Change" in the pharmacy ... for their future. "RBC is the ... their peers and learn new ways they can lead ...
(Date:7/23/2014)... CITY, Calif. , July 23, 2014  Cardica, Inc. ... release financial results for its fiscal fourth quarter and year ... the markets close. Cardica,s management will host a conference call ... and provide an update on the company,s business. ... August 7, 2014, at 4:30 p.m. Eastern Time via phone, ...
(Date:7/23/2014)... NEW YORK , July 23, 2014  Dompe, a ... of rare diseases, announces that rhNGF (Recombinant Human Nerve Growth ... American Food and Drug Administration (FDA). The ... designated as an orphan drug for the treatment of neurotrophic ... in 5,000 people 1 and is currently without a ...
Breaking Medicine Technology:Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 2Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 3Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 6Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 2Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 3Dompe announces the Food and Drug Administration (FDA) has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis 4
... 28, 2011 Streamline Health Solutions, Inc. (Nasdaq: ... workflow solutions for hospitals, announced today that two of ... system in North Carolina, contracted with Streamline Health to ... Resources, which began the beta phase of integration earlier ...
... Inc. (Nasdaq: PCRX ), an emerging specialty pharmaceutical ... quarter ended June 30, 2011 will be released before the ... team will host a conference call to discuss the company,s ... 11, 2011 at 9 a.m. ET. The call can be ...
Cached Medicine Technology:Streamline Health Announces Two Clients Have Contracted for Multiple Integrations to Their Epic Systems 2Streamline Health Announces Two Clients Have Contracted for Multiple Integrations to Their Epic Systems 3Streamline Health Announces Two Clients Have Contracted for Multiple Integrations to Their Epic Systems 4Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call 2
(Date:7/23/2014)... supports a growing body of research suggesting a ... in treating postmenopausal breast cancer, with fewer detrimental ... standard anti-hormone therapies. The study will be published ... Reproductive Biology and Endocrinology . , Breast ... women in the United States. Approximately 70% of ...
(Date:7/23/2014)... Global Cardio Care, Inc., a management company ... is celebrating the 100th birthday of Albert Weber, ... center. , Weber has been plagued with angina ... therapy since 1999, he no longer suffers from either ... Cardio Care, introduced the Sara Soulati Health For ...
(Date:7/23/2014)... The voice on the recording was low and calm as ... was infected with the human immunodeficiency virus (HIV) that causes AIDS: ... you know I was on the floor flat on my face ... when the recording ended less than 10 minutes later. “Don’t feel ... because it is just God setting you up for something greater,” ...
(Date:7/23/2014)... For patients infected with both HIV and hepatitis C, ... a small study suggests. Researchers said doctors could ... with the two diseases. "The findings suggest ... role in the management of individuals with [hepatitis C] ... a professor of medicine at the University of Cincinnati ...
(Date:7/23/2014)... Texas Physical Therapy Specialists (TexPTS) is ... Westlake, Westgate, Liberty Hill, Parmer, Balcones, and Georgetown clinics ... Orthopaedic Certified Specialist (OCS) or Sports ... DPT, OCS, Tony Lauretta, PT, DPT, OCS, Jason Brown, ... Leech, PT, DPT, OCS, and Mary Grimberg, PT, DPT, ...
Breaking Medicine News(10 mins):Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3Health News:HIV Meds May Also Help Control Hepatitis C, Study Finds 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3
... urge more awareness that long-term use has consequences , ... and other cardiovascular problems appear to be more common ... androgen deprivation therapy, which reduces or eliminates the male ... study has found. , The finding indicates that androgen ...
... Tamiflu Oral Suspension ... ... (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has begun shipping additional quantities of ... begin arriving in pharmacies nationwide and will continue to roll out to wholesale and retail ...
... The following is an op-ed written by Fredette West, Director, African ... how can the nation can pay for health reform; and in ... all the talk about finding "off-sets" -- media, legislators, and analysts, ... studies from Johns Hopkins University and the University of Maryland. A ...
... Initiates Training Program Partnering with Healthcare Employers , WEST ... a $134,790 grant by the State of Florida to fund ... for skilled health care workers in Palm Beach County. ... Healthcare Workforce Initiative. The funding enables Workforce Alliance to ...
... can,t teach an old dog new tricks," it,s often said. ... to be passed down from generation to generation. , "While some ... them and act on them," says Mark Nunez, DVM, president of ... veterinarian to find out if a commonly held belief is really ...
... ― Two medications approved as treatment for drug-resistant chronic ... responses as a first treatment than the existing front-line ... Anderson Cancer Center reported at the 51st Annual Meeting ... for CML remains imatinib, a Novartis drug known as ...
Cached Medicine News:Health News:Prostate Hormone Therapy May Up Heart Risks 2Health News:Prostate Hormone Therapy May Up Heart Risks 3Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 2Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 3Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 4Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 5Health News:Health Reform is About You and Me, Not One or the Other 2Health News:Health Reform is About You and Me, Not One or the Other 3Health News:Workforce Alliance Earns Grant to Train Health Care Workers 2Health News:Workforce Alliance Earns Grant to Train Health Care Workers 3Health News:Some Myths About Dogs and Cats Are Not Only False - They're Dangerous! 2Health News:Second-line CML drugs evoke faster response than front-line therapy 2
... Pump™ is a quiet, compact, efficient vacuum ... The oil-free design and TEFLON®/ETFE coated vapor ... reliability and reduced maintenance. Unique features include ... protection, and a 1-liter post-pump solvent recovery ...
Produces vacuum pressures required for 96 well kits...
... DirectPrep 96 plates and MinElute 96 ... sample handling and accelerated processing; ... plates and MinElute 96 UF PCR ... of internal components by simply separating ...
For vacuum-driven processing of spin columns; Reduced sample handling and accelerated processing; Parallel sample processing using QIAGEN spin columns; Easy cleaning of internal components by simpl...
Medicine Products: